From:  Epiploic appendagitis during rapid weight loss associated with tirzepatide therapy: a case report

 The timeline of the patient’s clinical event.

DateClinical eventWeight (kg)Weight (lb)Percent of change from prior weight (%)
Jun 2022Baseline weight117.72259.00-
Nov 16, 2022Tirzepatide increased to 5 mg weekly121.09266.40+2.86%
Dec 28, 2022Dose increased to 7.5 mg weekly---
Feb 7, 2023Dose increased to 10 mg weekly109.59241.10–9.50%
Mar 27, 2023Dose increased to 12.5 mg weekly101.36223.00–7.51%
Mar 31, 2023Acute right lower quadrant abdominal pain. CT abdomen/pelvis showed epiploic appendagitis at the level of the cecum101.36223.000.00%
Apr 2023Managed conservatively with NSAIDs and supportive care. Symptoms resolved. Tirzepatide was restarted at 10 mg with gradual titration101.36223.000.00%
Oct 2025 follow-upPatient on tirzepatide 15 mg weekly with no recurrence78.18172.00−22.87%

CT: computed tomography; NSAIDs: nonsteroidal anti-inflammatory drugs.